Medicare and Medicaid — the two largest government healthcare programs — collectively cover approximately 150 million Americans and determine the financial performance of every major payer, distributor, and pharmacy chain covered in this report. CMS reimbursement rules for Medicare Advantage, drug pricing under the Inflation Reduction Act, Medicaid managed care rate adequacy, and prior authorization reform are the four most consequential policy dynamics for the leading healthcare companies in 2025-2026. The 2025 Medicare Advantage rate notice — which reduced funding relative to industry expectations — was the primary driver of elevated medical cost ratios and margin pressure across the industry.
Topics Covered
• Medicare Advantage Rate Setting
• IRA Drug Pricing Provisions
• Medicaid Rate Adequacy
• Prior Authorization Reform Legislation
• CMS Innovation Center Models
• Government Program Strategy for Leading Companies
• Policy Outlook 2026-2030
Table of Contents
1. Executive Summary
2. Market and Policy Overview
3. Medicare Advantage Rate Setting
4. IRA Drug Pricing Provisions
5. Medicaid Rate Adequacy
6. Prior Authorization Reform Legislation
7. CMS Innovation Center Models
8. Government Program Strategy for Leading Companies
9. Policy Outlook 2026-2030
10. Strategic Conclusions and Recommendations
11. Appendix
List of Tables
Table 1. Policy and Market Overview 2025
Table 2. Medicare Advantage Rate Setting
Table 3. IRA Drug Pricing Provisions
Table 4. Medicaid Rate Adequacy
Table 5. Prior Authorization Reform Legislation
Table 6. CMS Innovation Center Models
Table 7. Government Program Strategy for Leading Companies
Table 8. Policy Outlook 2026-2030
Table 9. Leading Companies — Strategy and Response 2025
Table 10. Regulatory Timeline and Key Dates
Table 11. Key Risks and Mitigation Strategies
Companies Profiled
AbbVie
Bristol-Myers Squibb
CVS Caremark
Express Scripts
Humana Pharmacy
Johnson & Johnson
Merck
OptumRx
Pfizer
